Trading Ideas

Yahoo Finance’s Brian Sozzi and Alexis Christoforous break down Boeing’s latest earnings report with Peter McNally, Third Bridge Global Sector Lead. …read more […]

(Bloomberg) — Investors don’t seem too pleased with results from Blue Apron Holdings Inc.The shares dropped as much as 33% on Wednesday, their biggest slump in a month, after the spreading pandemic built up anticipation for Blue Apron’s meal-kit business. The stock had risen 450% from its March lows before Wednesday.The quarterly loss widened to $20.1 million compared to $5.3 million a year earlier. And if you check out key customer metrics, while orders are up from Dec. 31, they’re still solidly below the levels seen in the period ended March 31, 2019.Analysts were also expecting a greater increase in …read more […]

The plane-maker, already struggling after grounding the 737 Max, plans to axe 10% of its staff. …read more […]

…read more […]

U.S. stocks were poised to open higher Wednesday as upbeat data on coronavirus treatment from Gilead Sciences offset fresh figures that showed U.S. economic growth contracted in the first quarter. …read more […]

Gilead Sciences (GILD) has reported that it is aware of positive data emerging from the critical National Institute of Allergy and Infectious Diseases’ (NIAID) study of remdesivir for the treatment of COVID-19.“We understand that the trial has met its primary endpoint and that NIAID will provide detailed information at an upcoming briefing” the company said in a press release on April 29. Trading in the stock was briefly halted, before shares surged 9% in Wednesday’s pre-market trading.The randomized, controlled NIAID trial “has all the necessary scientific standards that are really going to help us define if this drug works or …read more […]

(Bloomberg) — Gilead Sciences Inc. said data from a U.S. study of its drug remdesivir showed the medication had met the primary endpoint in a trial of its effectiveness in treating Covid-19.The company said in a statement that it is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ study of remdesivir for treating the disease caused by the novel coronavirus.Gilead shares were halted, but the news appeared to lift the entire U.S. stock market, with futures linked to major U.S. indexes jumping after the company’s statement was issued.The U.S.-run trial looked at whether patients …read more […]

Warren Buffett, chairman and CEO of Berkshire Hathaway, has been a consistent voice of optimism on the U.S. economy and American innovation. …read more […]

Boeing Co CEO Dave Calhoun told employees on Wednesday that the largest U.S. planemaker is reducing the size of its workforce by about 10% amid a steep fall in travel demand due to the coronavirus pandemic. “We have begun taking action to lower our number of employees by roughly 10% through a combination of voluntary layoffs, natural turnover and involuntary layoffs as necessary,” Calhoun said in an email seen by Reuters. Boeing will need to make “even deeper reductions in areas that are most exposed to the condition of our commercial customers — more than 15% across …read more […]

…read more […]

(Bloomberg) — U.S President Donald Trump ordered meat-processing plants to stay open to stave off shortages and said confirmed cases had topped one million in the country because of better testing. Elon Musk hit out against the lockdowns that have kept businesses closed for more than a month.France and Spain took cautious steps toward reopening, while new cases rose for the first time in three days in Germany as the government weighs removing more curbs on public life. Beijing will lower its municipal emergency response as it prepares to host the nation’s highest-profile political meeting.GE said that the pandemic ‘materially …read more […]

Like its rival AstraZeneca , the British drugmaker stuck to its 2020 forecast and still expects a 1% to 4% fall in profit for the year. Analysts on average expected first-quarter adjusted earnings of 31.5 pence per share and sales of 8.75 billion pounds, according to a company-compiled consensus of 13 analysts. In the race to develop a vaccine to end the COVID-19 pandemic, governments, charities and Big Pharma firms are sinking billions of dollars into bets with extraordinarily low odds of success. …read more […]

This is sure to be one of the most controversial columns we ever publish.
It’s about politics.
It’s not about our politics. It’s not about your politics. It’s about politics and money.
If we don’t say it, we’re not sure who will.
In 2012, we penned a similar piece on the subject. We said one of the greatest risks to investors wasn’t a sudden shift in fundamentals or dwindling consumer demand.
America is strong, we said. She’s resilient. But she’s also quite a political beast.
For all the technological breakthroughs… for all the invention and innovation… for all the hard work… politics are the variable that …read more […]

The Boston-based conglomerate had earlier this month pulled its 2020 forecast, citing uncertainties created by the coronavirus outbreak, but backed its first-quarter industrial free cash flow expectation of near negative $2 billion. Free cash flow from industrial operations was negative $2.2 billion in the first quarter, missing analysts’ estimates of negative $2.02 billion, according to Refinitiv data. …read more […]

Shares in Wirecard slumped again on Wednesday as a prominent short seller demanded the sacking of CEO Markus Braun after a special audit of the German payments company was unable to verify its financial statements. Chris Hohn, head of $24 billion fund TCI, said in an open letter to Wirecard’s supervisory board that the audit by KPMG raised questions over management’s compliance with anti-money laundering and know-your-customer laws. “We are of the view that the supervisory board is legally obliged to intervene,” Hohn wrote in the letter, addressed to Wirecard Chairman Thomas Eichelmann and other supervisory board members. …read more […]